Sparsha Pharma International Pvt. Was established in 2008 as the first transdermal company in India to engage in R&D, manufacturing and marketing of transdermal products for global markets. Sparsha Pharma International Pvt.Ltd. Is India's first WHO certified Fentanyl Transdermal Patch manufacturer. The Hokunalin® Tape jointly developed in 1988 by Abbott Japan Co., Ltd and Nitto Denko was the world's first transdermal patch for treatment of asthma. Rusan's fentanyl-delivering patch Fenstud--Courtesy of Rusan. Mumbai, India's Rusan Pharma just inaugurated a $15 million facility dedicated to researching and manufacturing drug-delivering transdermal patches in Gujarat's Kandla special economic zone, dubbed the Navin Saxena Research and Technology center. But in India, doctors say, awareness of the use of transdermal patches in relieving pain is abysmally low. What’s more, these are not widely available in the country. “Indian companies started manufacturing these patches only half a decade ago.

Brand / Product Name Composition Strength Dosage Form Pack Size Therapeutic Category ALZAMINE 18 Each patch contains: Rivastigmine Base.18 mg 9.5 mg for 24 hours Transdermal Patches 5 Dementia ALZAMINE 9 Each patch contains: Rivastigmine Base.9 mg 4.6 mg for 24 hours Transdermal Patches 5 Dementia ASTHEROL Each transdermal patch contains: Tulobuterol.

Viper Youtube Video Gallery Pro. Patch it up Transdermal patches can help in pain management. But there is not enough awareness about them in India, says Hemchhaya De You have heard of nicotine patches — those Band Aid-like strips that help people quit smoking. But those are just one variety of what is broadly known as transdermal patches.

The latter play a crucial role in pain management in several parts of the world. But in India, doctors say, awareness of the use of transdermal patches in relieving pain is abysmally low. What’s more, these are not widely available in the country. “Indian companies started manufacturing these patches only half a decade ago. But awareness is still quite low,” says Dr G.P. Dureja, director, Delhi Pain Management Centre, who started pain management services at Delhi’s All India Institute of Medical Sciences in 1986.

Agrees Sanjay Singh, business unit head, Sparsha Pharma, one of the few drug companies in the country manufacturing patches, “There is a huge demand for transdermal patches in therapeutic areas like cancer, asthma and Alzheimer’s. Unfortunately, there is not much awareness in India with regard to transdermal application of drugs.” Dr Dureja adds that pain is considered a major health problem all over the world. “About 80 per cent of the patients visiting any hospital or doctor have pain as their major complaint. It can be severe and can damage the nervous system.” Furthermore, chronic pain affects approximately 30 per cent of the adult Indian population, especially women and the elderly. Doctors stress that this is where transdermal patches — adhesive skin patches that are used to deliver drugs through the skin and into the bloodstream — can make a world of difference.